Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 5, 2013

Waters Corporation Announces CEO Transition Plan

Author(s)Melanie Sena

CEO of Waters Corporation will retire within in the next two years.

Waters Corporation announced that Douglas A. Berthiaume will retire as CEO within the next two years.

The company’s board of directors has appointed a succession planning committee that will guide the process of selecting a successor and plans to hire an executive search firm to assist in a search, which will consider both internal and external candidates.

Berthiaume, who is 64, was appointed president and CEO of Waters Corporation in 1994 when the business was separated from Millipore, and assumed the additional role of chairman in 1996.

Source: Waters Corporation


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.